Under the technology agreement Activiomics will use its mass spectrometry-based TIQUAS platform to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.
The company, called Activiomics, last week announced a collaboration with GlaxoSmithKline that will use its TIQUAS technology to analyze novel inflammatory pathways by identifying biomarkers and validating targets.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.